Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers

Kun Huei Yeh, Chi Long Chen, Chia Tung Shun, Jaw Town Lin, Wei Jei Lee, Po Huang Lee, Yao Chang Chen, Ann Lii Cheng

研究成果: 雜誌貢獻文章

14 引文 (Scopus)

摘要

The mechanism of drug resistance of gastric cancer cells has rarely been investigated. We specifically examine the magnitude and the biologic significance of multidrug resistance-1 (MDR-1) expression in human gastric cancer. All patients had previously been treated in prospective clinical trials for advanced gastric cancer in our institution. Patients with adequate prechemotherapy gastric cancer tissues for immunohistochemical studies by a C219 monoclonal antibody were selected for the determination of the expression rate of MDR-1. The results were designated as negative or positive by the independent interpretation of two pathologists. A subgroup of patients who had been treated with doxorubicin- or etoposide-containing regimens were selected for further correlation with drug sensitivity. Between 1990 and 1996, a total of 60 patients, 38 men and 22 women with a median age of 55 years, were studied. Eight (13.3%; 95% confidence interval, 6%-25%) of them had MDR-1 expression. None of the pertinent clinicopathologic features, including the histopathologic types of the tumors and the extent of the diseases, correlated with the expression of MDR-1. Among the 30 patients who had received doxorubicin- or etoposide-containing combination chemotherapy, 3 (10%; 95% confidence interval, 3%-27%) were designated positive for MDR-1 expression. None of the 3 patients responded to chemotherapy, whereas 19 (70.4%) of the 27 patients who had not expressed MDR-1 did respond (p = 0.041 by Fisher's exact test). We conclude that the expression of MDR-1 in gastric cancer is relatively low. Its expression, however, is clinically relevant and is useful in predicting the chemoresistance of patients with gastric cancer receiving doxorubicin- or etoposide-containing combination chemotherapy.

原文英語
頁(從 - 到)274-278
頁數5
期刊Journal of Clinical Gastroenterology
26
發行號4
DOIs
出版狀態已發佈 - 1998
對外發佈Yes

指紋

Multiple Drug Resistance
Stomach Neoplasms
Etoposide
Doxorubicin
Combination Drug Therapy
Confidence Intervals
Drug Resistance
Monoclonal Antibodies
Clinical Trials
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Gastroenterology

引用此文

Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. / Yeh, Kun Huei; Chen, Chi Long; Shun, Chia Tung; Lin, Jaw Town; Lee, Wei Jei; Lee, Po Huang; Chen, Yao Chang; Cheng, Ann Lii.

於: Journal of Clinical Gastroenterology, 卷 26, 編號 4, 1998, p. 274-278.

研究成果: 雜誌貢獻文章

Yeh, Kun Huei ; Chen, Chi Long ; Shun, Chia Tung ; Lin, Jaw Town ; Lee, Wei Jei ; Lee, Po Huang ; Chen, Yao Chang ; Cheng, Ann Lii. / Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. 於: Journal of Clinical Gastroenterology. 1998 ; 卷 26, 編號 4. 頁 274-278.
@article{a249520f41aa4071882af994d4e6f8e4,
title = "Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers",
abstract = "The mechanism of drug resistance of gastric cancer cells has rarely been investigated. We specifically examine the magnitude and the biologic significance of multidrug resistance-1 (MDR-1) expression in human gastric cancer. All patients had previously been treated in prospective clinical trials for advanced gastric cancer in our institution. Patients with adequate prechemotherapy gastric cancer tissues for immunohistochemical studies by a C219 monoclonal antibody were selected for the determination of the expression rate of MDR-1. The results were designated as negative or positive by the independent interpretation of two pathologists. A subgroup of patients who had been treated with doxorubicin- or etoposide-containing regimens were selected for further correlation with drug sensitivity. Between 1990 and 1996, a total of 60 patients, 38 men and 22 women with a median age of 55 years, were studied. Eight (13.3{\%}; 95{\%} confidence interval, 6{\%}-25{\%}) of them had MDR-1 expression. None of the pertinent clinicopathologic features, including the histopathologic types of the tumors and the extent of the diseases, correlated with the expression of MDR-1. Among the 30 patients who had received doxorubicin- or etoposide-containing combination chemotherapy, 3 (10{\%}; 95{\%} confidence interval, 3{\%}-27{\%}) were designated positive for MDR-1 expression. None of the 3 patients responded to chemotherapy, whereas 19 (70.4{\%}) of the 27 patients who had not expressed MDR-1 did respond (p = 0.041 by Fisher's exact test). We conclude that the expression of MDR-1 in gastric cancer is relatively low. Its expression, however, is clinically relevant and is useful in predicting the chemoresistance of patients with gastric cancer receiving doxorubicin- or etoposide-containing combination chemotherapy.",
keywords = "Gastric cancer, Multidrug resistance- 1 (MDR- 1)",
author = "Yeh, {Kun Huei} and Chen, {Chi Long} and Shun, {Chia Tung} and Lin, {Jaw Town} and Lee, {Wei Jei} and Lee, {Po Huang} and Chen, {Yao Chang} and Cheng, {Ann Lii}",
year = "1998",
doi = "10.1097/00004836-199806000-00012",
language = "English",
volume = "26",
pages = "274--278",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers

AU - Yeh, Kun Huei

AU - Chen, Chi Long

AU - Shun, Chia Tung

AU - Lin, Jaw Town

AU - Lee, Wei Jei

AU - Lee, Po Huang

AU - Chen, Yao Chang

AU - Cheng, Ann Lii

PY - 1998

Y1 - 1998

N2 - The mechanism of drug resistance of gastric cancer cells has rarely been investigated. We specifically examine the magnitude and the biologic significance of multidrug resistance-1 (MDR-1) expression in human gastric cancer. All patients had previously been treated in prospective clinical trials for advanced gastric cancer in our institution. Patients with adequate prechemotherapy gastric cancer tissues for immunohistochemical studies by a C219 monoclonal antibody were selected for the determination of the expression rate of MDR-1. The results were designated as negative or positive by the independent interpretation of two pathologists. A subgroup of patients who had been treated with doxorubicin- or etoposide-containing regimens were selected for further correlation with drug sensitivity. Between 1990 and 1996, a total of 60 patients, 38 men and 22 women with a median age of 55 years, were studied. Eight (13.3%; 95% confidence interval, 6%-25%) of them had MDR-1 expression. None of the pertinent clinicopathologic features, including the histopathologic types of the tumors and the extent of the diseases, correlated with the expression of MDR-1. Among the 30 patients who had received doxorubicin- or etoposide-containing combination chemotherapy, 3 (10%; 95% confidence interval, 3%-27%) were designated positive for MDR-1 expression. None of the 3 patients responded to chemotherapy, whereas 19 (70.4%) of the 27 patients who had not expressed MDR-1 did respond (p = 0.041 by Fisher's exact test). We conclude that the expression of MDR-1 in gastric cancer is relatively low. Its expression, however, is clinically relevant and is useful in predicting the chemoresistance of patients with gastric cancer receiving doxorubicin- or etoposide-containing combination chemotherapy.

AB - The mechanism of drug resistance of gastric cancer cells has rarely been investigated. We specifically examine the magnitude and the biologic significance of multidrug resistance-1 (MDR-1) expression in human gastric cancer. All patients had previously been treated in prospective clinical trials for advanced gastric cancer in our institution. Patients with adequate prechemotherapy gastric cancer tissues for immunohistochemical studies by a C219 monoclonal antibody were selected for the determination of the expression rate of MDR-1. The results were designated as negative or positive by the independent interpretation of two pathologists. A subgroup of patients who had been treated with doxorubicin- or etoposide-containing regimens were selected for further correlation with drug sensitivity. Between 1990 and 1996, a total of 60 patients, 38 men and 22 women with a median age of 55 years, were studied. Eight (13.3%; 95% confidence interval, 6%-25%) of them had MDR-1 expression. None of the pertinent clinicopathologic features, including the histopathologic types of the tumors and the extent of the diseases, correlated with the expression of MDR-1. Among the 30 patients who had received doxorubicin- or etoposide-containing combination chemotherapy, 3 (10%; 95% confidence interval, 3%-27%) were designated positive for MDR-1 expression. None of the 3 patients responded to chemotherapy, whereas 19 (70.4%) of the 27 patients who had not expressed MDR-1 did respond (p = 0.041 by Fisher's exact test). We conclude that the expression of MDR-1 in gastric cancer is relatively low. Its expression, however, is clinically relevant and is useful in predicting the chemoresistance of patients with gastric cancer receiving doxorubicin- or etoposide-containing combination chemotherapy.

KW - Gastric cancer

KW - Multidrug resistance- 1 (MDR- 1)

UR - http://www.scopus.com/inward/record.url?scp=0031775882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031775882&partnerID=8YFLogxK

U2 - 10.1097/00004836-199806000-00012

DO - 10.1097/00004836-199806000-00012

M3 - Article

C2 - 9649010

AN - SCOPUS:0031775882

VL - 26

SP - 274

EP - 278

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 4

ER -